355 related articles for article (PubMed ID: 34187458)
1. Healthcare provider and pregnant women's perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin-piperaquine for malaria in pregnancy in western Kenya: a qualitative study.
Hoyt J; Hill J; Achieng F; Ouma P; Kariuki S; Desai M; Webster J
Malar J; 2021 Jun; 20(1):291. PubMed ID: 34187458
[TBL] [Abstract][Full Text] [Related]
2. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya.
Hill J; Ouma P; Oluoch S; Bruce J; Kariuki S; Desai M; Webster J
Malar J; 2020 Nov; 19(1):433. PubMed ID: 33238999
[TBL] [Abstract][Full Text] [Related]
3. User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya.
Hill J; Hoyt J; Achieng F; Ouma P; L'lanziva A; Kariuki S; Desai M; Webster J
PLoS One; 2016; 11(3):e0150259. PubMed ID: 26986471
[TBL] [Abstract][Full Text] [Related]
4. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.
Madanitsa M; Kalilani L; Mwapasa V; van Eijk AM; Khairallah C; Ali D; Pace C; Smedley J; Thwai KL; Levitt B; Wang D; Kang'ombe A; Faragher B; Taylor SM; Meshnick S; Ter Kuile FO
PLoS Med; 2016 Sep; 13(9):e1002124. PubMed ID: 27622558
[TBL] [Abstract][Full Text] [Related]
5. Intermittent screening and treatment or intermittent preventive treatment compared to current policy of single screening and treatment for the prevention of malaria in pregnancy in Eastern Indonesia: acceptability among health providers and pregnant women.
Hoyt J; Landuwulang CUR; Ansariadi ; Ahmed R; Burdam FH; Bonsapia I; Poespoprodjo JR; Syafruddin D; Ter Kuile FO; Webster J; Hill J
Malar J; 2018 Sep; 17(1):341. PubMed ID: 30261877
[TBL] [Abstract][Full Text] [Related]
6. Provider and user acceptability of intermittent screening and treatment for the control of malaria in pregnancy in Malawi.
Almond D; Madanitsa M; Mwapasa V; Kalilani-Phiri L; Webster J; Ter Kuile F; Paintain L
Malar J; 2016 Nov; 15(1):574. PubMed ID: 27894353
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
8. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial.
Kabuya JB; Ippolito MM; Sikalima J; Tende C; Champo D; Mwakazanga D; Young AMP; Mulenga M; Chongwe G; Manyando C
Trials; 2021 Nov; 22(1):820. PubMed ID: 34801059
[TBL] [Abstract][Full Text] [Related]
10. An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context.
Aberese-Ako M; Magnussen P; Ampofo GD; Gyapong M; Ansah E; Tagbor H
PLoS One; 2021; 16(10):e0257666. PubMed ID: 34618812
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting uptake of ≥ 3 doses of Sulfadoxine-Pyrimethamine for malaria prevention in pregnancy in selected health facilities, Arusha region, Tanzania.
Mchwampaka WM; Tarimo D; Chacky F; Mohamed A; Kishimba R; Samwel A
BMC Pregnancy Childbirth; 2019 Nov; 19(1):440. PubMed ID: 31775686
[TBL] [Abstract][Full Text] [Related]
12. A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Tagbor H; Cairns M; Bojang K; Coulibaly SO; Kayentao K; Williams J; Abubakar I; Akor F; Mohammed K; Bationo R; Dabira E; Soulama A; Djimdé M; Guirou E; Awine T; Quaye S; Njie F; Ordi J; Doumbo O; Hodgson A; Oduro A; Meshnick S; Taylor S; Magnussen P; ter Kuile F; Woukeu A; Milligan P; Chandramohan D; Greenwood B
PLoS One; 2015; 10(8):e0132247. PubMed ID: 26258474
[TBL] [Abstract][Full Text] [Related]
13. Provision and uptake of routine antenatal services: a qualitative evidence synthesis.
Downe S; Finlayson K; Tunçalp Ö; Gülmezoglu AM
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012392. PubMed ID: 31194903
[TBL] [Abstract][Full Text] [Related]
14. Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial.
Kakuru A; Jagannathan P; Kajubi R; Ochieng T; Ochokoru H; Nakalembe M; Clark TD; Ruel T; Staedke SG; Chandramohan D; Havlir DV; Kamya MR; Dorsey G
BMC Med; 2020 Aug; 18(1):207. PubMed ID: 32772921
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy.
Olaleye A; Okusanya BO; Oduwole O; Esu E; Meremikwu M
Int J Gynaecol Obstet; 2019 Jul; 146(1):43-55. PubMed ID: 31050803
[TBL] [Abstract][Full Text] [Related]
16. Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania.
Mubyazi G; Bloch P; Kamugisha M; Kitua A; Ijumba J
Malar J; 2005 Jul; 4():31. PubMed ID: 16033639
[TBL] [Abstract][Full Text] [Related]
17. Antenatal visits are positively associated with uptake of tetanus toxoid and intermittent preventive treatment in pregnancy in Ivory Coast.
Yaya S; Kota K; Buh A; Bishwajit G
BMC Public Health; 2019 Nov; 19(1):1467. PubMed ID: 31694607
[TBL] [Abstract][Full Text] [Related]
18. Perspectives of health care providers on the provision of intermittent preventive treatment in pregnancy in health facilities in Malawi.
Yoder PS; Nsabagasani X; Eckert E; Moran A; Yé Y
BMC Health Serv Res; 2015 Aug; 15():354. PubMed ID: 26318623
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with uptake of optimal doses of intermittent preventive treatment for malaria among pregnant women in Uganda: analysis of data from the Uganda Demographic and Health Survey, 2016.
Okethwangu D; Opigo J; Atugonza S; Kizza CT; Nabatanzi M; Biribawa C; Kyabayinze D; Ario AR
Malar J; 2019 Jul; 18(1):250. PubMed ID: 31349829
[TBL] [Abstract][Full Text] [Related]
20. Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Esu E; Berens-Riha N; Pritsch M; Nwachuku N; Loescher T; Meremikwu M
Malar J; 2018 Jul; 17(1):251. PubMed ID: 29976228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
